LIXT — Lixte Biotechnology Holdings Share Price
0.000.00%
Last trade - 00:00- $5.33m
- $5.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -149.94% | ||
| Return on Equity | -4527.7% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.
Directors
- John Kovach CHM (84)
- Robert Weingarten CFO (68)
- Eric Forman CAD (41)
- James Miser OTH (73)
- Gil Schwartzberg DRC
- Regina Brown IND
- Stephen Forman IND (72)
- Philip Palmedo IND (86)
- Yun Yen IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 24th, 2005
- Public Since
- September 21st, 2007
- No. of Shareholders
- 46
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,249,290
- Address
- No. 2, 248 Route 25A, EAST SETAUKET, 11733
- Web
- https://lixte.com/
- Phone
- +1 3102032902
- Auditors
- WEINBERG & COMPANY PA
Upcoming Events for LIXT
Q3 2024 Lixte Biotechnology Holdings Inc Earnings Release
Lixte Biotechnology Holdings Inc Annual Shareholders Meeting
Similar to LIXT
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Lixte Biotechnology Holdings share price?
As of Today at 21:51 UTC, shares in Lixte Biotechnology Holdings are trading at $2.54. This share price information is delayed by 15 minutes.
How has the Lixte Biotechnology Holdings share price performed this year?
Shares in Lixte Biotechnology Holdings last closed at $2.54 and the price had moved by -52.19% over the past 365 days. In terms of relative price strength the Lixte Biotechnology Holdings share price has underperformed the S&P500 Index by -61.96% over the past year.
What are the analyst and broker recommendations for Lixte Biotechnology Holdings?
There is no consensus recommendation for this security.
What is the Lixte Biotechnology Holdings dividend yield?
Lixte Biotechnology Holdings does not currently pay a dividend.
Does Lixte Biotechnology Holdings pay a dividend?
Lixte Biotechnology Holdings does not currently pay a dividend.
When does Lixte Biotechnology Holdings next pay dividends?
Lixte Biotechnology Holdings does not currently pay a dividend.
How do I buy Lixte Biotechnology Holdings shares?
To buy shares in Lixte Biotechnology Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lixte Biotechnology Holdings?
As of the previous close price of $2.54, shares in Lixte Biotechnology Holdings had a market capitalisation of $5.71m.
Where are Lixte Biotechnology Holdings shares listed?
Here are the trading details for Lixte Biotechnology Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LIXT
What kind of share is Lixte Biotechnology Holdings?
Based on an overall assessment of its quality, value and momentum Lixte Biotechnology Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lixte Biotechnology Holdings share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Lixte Biotechnology Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lixte Biotechnology Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -0.48%.
As of the last closing price of $2.54, shares in Lixte Biotechnology Holdings were trading +1.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lixte Biotechnology Holdings PE Ratio?
The Lixte Biotechnology Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings' management team is headed by:
- John Kovach - CHM
- Robert Weingarten - CFO
- Eric Forman - CAD
- James Miser - OTH
- Gil Schwartzberg - DRC
- Regina Brown - IND
- Stephen Forman - IND
- Philip Palmedo - IND
- Yun Yen - IND